Edwards Lifesciences Corporation
EW
$67.95
-$0.56-0.82%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 1.39B | 1.35B | 1.35B | 1.35B | 1.27B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.39B | 1.35B | 1.35B | 1.35B | 1.27B |
| Cost of Revenue | 292.20M | 262.90M | 266.10M | 296.30M | 251.00M |
| Gross Profit | 1.09B | 1.09B | 1.09B | 1.05B | 1.02B |
| SG&A Expenses | 491.30M | 421.40M | 443.10M | 432.80M | 415.40M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -22.70M | 22.40M | 0.00 | -- | -176.00M |
| Total Operating Expenses | 1.03B | 960.10M | 979.90M | 986.90M | 732.50M |
| Operating Income | 353.90M | 394.30M | 372.50M | 360.00M | 533.90M |
| Income Before Tax | 390.10M | 402.80M | 381.90M | 373.30M | 367.20M |
| Income Tax Expenses | 45.10M | 40.70M | 19.70M | 46.60M | 34.10M |
| Earnings from Continuing Operations | 345.00M | 362.10M | 362.20M | 326.70M | 333.10M |
| Earnings from Discontinued Operations | 39.30M | 2.71B | 2.80M | 24.30M | 36.60M |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 1.30M | 1.40M | 1.30M | 900.00K | 200.00K |
| Net Income | 385.60M | 3.07B | 366.30M | 351.90M | 369.90M |
| EBIT | 353.90M | 394.30M | 372.50M | 360.00M | 533.90M |
| EBITDA | 396.50M | 428.80M | 412.10M | 398.50M | 570.60M |
| EPS Basic | 0.65 | 5.14 | 0.61 | 0.59 | 0.61 |
| Normalized Basic EPS | 0.40 | 0.47 | 0.41 | 0.40 | 0.56 |
| EPS Diluted | 0.65 | 5.14 | 0.61 | 0.58 | 0.61 |
| Normalized Diluted EPS | 0.40 | 0.47 | 0.41 | 0.40 | 0.56 |
| Average Basic Shares Outstanding | 589.80M | 597.20M | 602.10M | 601.50M | 605.20M |
| Average Diluted Shares Outstanding | 590.50M | 598.10M | 604.30M | 604.10M | 606.90M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
